Genmab A/s Stock News

Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd. , Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co. Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd. , Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co.

Media Release COPENHAGEN, Denmark, and BOTHELL, Wash., February 24, 2022

BOTHELL, Wash., & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) will present preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (TIVDAK®) as a monotherapy in patients with squamous cell carcinoma of the head and neck (SCCHN) who experienced disease progression on or after a first-line platinum-containing regimen and a checkpoint inhibitor. Early results showed tisotumab vedotin demonstrated a

GMAB earnings call for the period ending December 31, 2021.

GMAB earnings call for the period ending December 31, 2021.

Genmab AS Earnings, Revenue Beat in Q4

Genmab A/S (GMAB) CEO Jan van de Winkel on Q4 2021 Results - Earning Calls Transcript

Genmab A/S (NASDAQ:GMAB) is scheduled to announce FY earnings results on Wednesday, Feb. 16, before market open.The consensus EPS estimate is $6.50

Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago quarter EPS of $2.25.

Genmab has an impressive pipeline of proprietary and partnered programs in development. In addition, the company has developed or helped develop five FDA-approved monoclonal antibody therapies. The co

Genmab A/S (NASDAQ:GMAB) was the recipient of a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 1,920,000 shares, a growth of 34.3% from the November 15th total of 1,430,000 shares. Based on an average daily trading volume, of 368,600 shares, the short-interest ratio is [] The post Genmab A/S (NASDAQ:GMAB) Short Interest Up 34.3% in November appeared first on ETF Daily News .

Moloney Securities Asset Management LLC lessened its stake in Genmab A/S (NASDAQ:GMAB) by 8.2% during the third quarter, Holdings Channel reports. The firm owned 4,736 shares of the companys stock after selling 424 shares during the period. Moloney Securities Asset Management LLCs holdings in Genmab A/S were worth $207,000 as of its most recent SEC []